ArticleEuropean journal of public health2026
SARS-CoV-2 testing uptake and its determinants in six ethnic groups living in Amsterdam, the Netherlands: a registry-based study within the HELIUS cohort.
Article in European journal of public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Diagnostic testing was key in preventing transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the pre-vaccination era of the coronavirus disease 2019 pandemic. This study compared SARS-CoV-2 polymerase chain reaction (PCR) testing uptake and its determinants across six ethnic groups in Amsterdam, the Netherlands. We analyzed data from the population-based Healthy Life in an Urban Setting cohort linked to SARS-CoV-2 testing registry data from the Public Health Service of Amsterdam. Testing uptake was defined as completing at least one SARS-CoV-2 PCR test before 6 September 2021. We examined the association between ethnicity and testing uptake, and assessed determinants of testing uptake per ethnic group, using logistic regression while correcting for ethnic-specific age and sex distributions in Amsterdam. We included 19 006 participants (median age 53 years; 57% female). Testing uptake ranged from 25.3% (95% confidence interval (CI) = 23.1%-27.5%) in the Ghanaian to 52.2% (95% CI = 50.3%-54.1%) in the Turkish group. Individuals of Turkish origin [adjusted odds ratio (aOR) = 1.12, 95% CI = 1.01-1.23] were more likely, while those of African Surinamese (aOR = 0.88, 95% CI = 0.79-0.97) and particularly Ghanaian (aOR = 0.35, 95% CI = 0.30-0.40) origin less likely to be tested compared to those of Dutch origin. Younger age and perceived work or home-related stress were associated with testing uptake across most ethnic groups. Other determinants were specific to certain groups. SARS-CoV-2 testing uptake varied slightly across most ethnic groups in Amsterdam with the highest uptake among individuals of Turkish origin but was remarkably lower among individuals of Ghanaian origin. Given the diversity of identified determinants, testing strategies should be tailored to the needs of specific groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.